SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review

Maxson, Rebecca; Starr, Jessica; Sewell, Jeanna; Lyas, Claretha

doi:10.1016/j.clinthera.2023.10.014

Cited by 7 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent structure-activity relationship investigations showed that both the glucose core and substitution at the C-1 position are critical for α-PGG to mediate its potential antidiabetic activity, which was enhanced by the introduction of a chlorine atom [87][88][89]. Based on these conclusions, an FDA-approved antidiabetic drug, dapagliflozin, has been developed using glucose as a template, with a chlorine-bearing phenyl moiety being substituted directly at the C-1 position [90][91][92]. This example indicates that other therapeutic agents may be developed from elderberry constituents.…”

Section: Discussionmentioning

confidence: 99%

“…As a potent SGLT-2 inhibitor, dapagliflozin also reduces body weight, lowers blood pressure, and decreases the occurrence of cardiovascular incidents and renal complications in T2DM patients. As a result, this agent has successfully been used to treat diabetes, heart failure, and kidney disease [90][91][92]. Thus, dapagliflozin was approved by the FDA in 2014 for the treatment of diabetes (https: //www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000TOC.cfm, accessed on 6 May 2024).…”

Section: Development Of Potential Therapeutic Agents From the Major S...mentioning

confidence: 99%

See 1 more Smart Citation

Development of Potential Therapeutic Agents from Black Elderberries (the Fruits of Sambucus nigra L.)

Ren,

Meyer,

Anderson

et al. 2024

Molecules

View full text Add to dashboard Cite

Elderberry (Sambucus nigra L.) is a widespread deciduous shrub, of which the fruits (elderberries) are used in the food industry to produce different types of dietary supplement products. These berries have been found to show multiple bioactivities, including antidiabetic, anti-infective, antineoplastic, anti-obesity, and antioxidant activities. An elderberry extract product, Sambucol®, has also been used clinically for the treatment of viral respiratory infections. As the major components, phenolic compounds, such as simple phenolic acids, anthocyanins and other flavonoids, and tannins, show promising pharmacological effects that could account for the bioactivities observed for elderberries. Based on these components, salicylic acid and its acetate derivative, aspirin, have long been used for the treatment of different disorders. Dapagliflozin, an FDA-approved antidiabetic drug, has been developed based on the conclusions obtained from a structure–activity relationship study for a simple hydrolyzable tannin, β-pentagalloylglucoside (β-PGG). Thus, the present review focuses on the development of therapeutic agents from elderberries and their small-molecule secondary metabolites. It is hoped that this contribution will support future investigations on elderberries.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Development Of Potential Therapeutic Agents From the Major S...mentioning

confidence: 99%

Development of Potential Therapeutic Agents from Black Elderberries (the Fruits of Sambucus nigra L.)

Ren,

Meyer,

Anderson

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights

Capelli,

Lerario,

Ciurli

et al. 2024

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Lonardo

2024

Metab Target Organ Damage

View full text Add to dashboard Cite

Chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) account for substantial financial burden worldwide. These alarming features call for enhanced efforts to prevent and manage the development and progression of CKD. Accumulating evidence supporting a causal role of NAFLD/MAFLD/MASLD-in CKD opens new horizons to achieve this aim. Recent epidemiological studies and meta-analyses exploring the association of NAFLD/MAFLD/MASLD with CKD and the characteristics of NAFLD/MAFLD/MASLD associated with the odds of incident CKD are discussed. The involved pathomechanisms, including the common soil hypothesis, genetics, gut dysbiosis, and portal hypertension, are examined in detail. Finally, lifestyle changes (diet and physical exercise), direct manipulation of gut microbiota, and drug approaches involving statins, renin-angiotensin-aldosterone system inhibitors, GLP-1 Receptor Agonists, Sodium-glucose cotransporter-2, pemafibrate, and vonafexor are examined within the context of prevention and management of CKD among those with NAFLD/MAFLD/MASLD. The evolving NAFLD/MAFLD/MASLD nomenclature may generate confusion among practicing clinicians and investigators. However, comparative studies investigating the pros and contra of different nomenclatures may identify the most useful definitions among NAFLD/MAFLD/MASLD and strategies to identify, prevent, and halt the onset and progression of CKD.

show abstract

SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review

Cited by 7 publications

References 25 publications

Development of Potential Therapeutic Agents from Black Elderberries (the Fruits of Sambucus nigra L.)

Development of Potential Therapeutic Agents from Black Elderberries (the Fruits of Sambucus nigra L.)

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Contact Info

Product

Resources

About